Global Encephalitis Vaccines Market Size To Exceed USD 42.2 Billion by 2032 | CAGR of 8.1%

Global Encephalitis Vaccines Market To Exceed USD 42.2 Billion by 2032

According to a research report published by Spherical Insights & Consulting Global Encephalitis Vaccines Market Size is to grow from USD 19.36 billion in 2022 to USD 42.2 billion by 2032, at a Compound Annual Growth Rate (CAGR) of 8.1% % during the forecast period.

Browse key industry insights spread across 200 pages with 100 market data tables and figures & charts from the report on "Global Encephalitis Vaccines Market Size, Share, and COVID-19 Impact Analysis, By Vaccine Type (Mouse Brain-Derived Inactivated Vaccine, Cell Culture-Derived Inactivated Vaccine, Cell Culture-Derived Live Attenuated Vaccine), Indication Type (Japanese Encephalitis, Tick-Borne Encephalitis, Rabies Encephalitis), End-User (Child, and Adult), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022– 2032". Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/encephalitis-vaccines-market

The encephalitis virus is a mosquito-borne Flavivirus that multiplies in amplifying vertebrate hosts like pigs and wading birds through an enzootic cycle. Immunizations make it simple to avoid. It is the leading cause of encephalitis in Asia-Pacific. The encephalitis virus is easily transmitted to people by a mosquito bite, and it is particularly prevalent in rural agricultural areas. The risk of getting the encephalitis virus is minimal, although it can occur for varying lengths of time, in different places, and during different activities. A key factor driving the market's expansion is the high mortality and morbidity rate brought on by the presence of the encephalitis virus. Additionally, the business is being driven by a rise in government immunization program activities. As of April 28, 2022, four Australian states have been recognized as having 37 human cases of Japanese encephalitis (25 laboratory-confirmed cases and 12 suspected cases), according to the World Health Organization.

One major driving factor is the increasing incidence of encephalitis, which includes viral illnesses like Japanese encephalitis, tick-borne encephalitis, and others. Additionally, the prevalence of encephalitis cases around the globe highlights the necessity for efficient preventative measures, such as immunizations. Additionally, governments across the world, particularly in areas with a high prevalence of encephalitis, are aggressively supporting immunization programs. In addition, governments and international organizations frequently incorporate encephalitis vaccinations in extended immunization efforts. Additionally, the inclusion of these vaccinations in regular immunization regimens raises interest in and demand for them. The creation of fresh and better encephalitis vaccines is also aided by pharmaceutical businesses and governmental organizations investing in research and development. These financial commitments support market growth and innovation. Furthermore, the cost of encephalitis vaccinations can be high, especially in underdeveloped nations with constrained healthcare resources. Due to their high price, vaccinations may not be as accessible or affordable for low-income communities, which would restrict their market penetration.

COVID 19 Impact

Because of lockdowns and limitations on non-emergency hospital visits, the COVID-19 pandemic had a significant impact on the market that was being examined in the early months of the pandemic. This prevented individuals from getting the vaccines they had planned. The business was able to pick up steam after the COVID-19 pandemic was under control in 2021 and vaccinations restarted. Numerous investigations showed that the COVID-19 vaccine has a low incidence of encephalitis side effects. Due to the current worldwide pandemic, vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) have been distributed worldwide; however, incidences of SARS-CoV-2 vaccination-related encephalitis have only occasionally been documented, according to the study "Acute encephalitis after COVID-19 vaccination: A case report and literature review" published in February 2022. Therefore, the industry was considerably influenced by the rising incidence of encephalitis following COVID-19 immunization.

The Cell culture-derived inactivated vaccines segment is influencing the market with the largest market share over the forecast period.

On the basis of vaccine type, the global encephalitis vaccines market is bifurcated into several segments such as, mouse brain-derived inactivated vaccine, cell culture-derived Inactivated Vaccine and Cell Culture-Derived Live Attenuated Vaccine. Cell culture-derived inactivated vaccines are the sector with the fastest market growth among them. Due to their efficiency and safety, cell culture-derived inactivated vaccines have become more popular. To create these vaccines, the virus is grown in cell cultures, rendered inactive, and then used to elicit an immune response. Inactivated vaccines made from mouse brains formerly required the use of mouse brain tissue; this production approach does not require it.

The Japanese Encephalitis (JE) vaccine segment is dominating the largest market growth during the forecast period.

The global market for encephalitis vaccines is divided into many divisions based on the kind of encephalitis they are used to prevent, including Japanese encephalitis, tick-borne encephalitis, and rabies encephalitis. Over the projected period, it is anticipated that the Japanese encephalitis (JE) vaccine sector would expand significantly. Mosquitoes are the main source of the virus that causes Japanese encephalitis, which is mostly found in Asia. In a lot of the nations in the area, it is the main cause of viral encephalitis. The need for JE vaccines has grown significantly, especially in nations where the disease is endemic, as a result of the high prevalence and effects of the illness. Government activities to develop JE vaccines also help to fuel this market. National immunization programs that involve widespread vaccination have been created by the Indian government. For instance, the chief medical officer of Nainital started a comprehensive immunization campaign against Japanese encephalitis in July 2022 for children between the ages of 1 and 15 in both private and public schools.

Asia Pacific is leading the market with the largest market growth over the forecast period

Throughout the projection period, it is predicted that the Asia-Pacific market would expand exponentially. In Asian nations, Japanese encephalitis is prevalent. The Japanese encephalitis virus, according to the updates from the European Centre for Disease Prevention and Control in March 2022, is spread throughout Asia and Oceania, from Japan to India, Pakistan, and Australia. The geography and timing of outbreaks make them unpredictable, chaotic, and sporadic. Every year, between 30,000 and 50,000 cases are reported, and the virus is a major contributor to viral encephalitis in Asia. As a result, the rising prevalence of encephalitis in the area has benefited market expansion throughout the predicted period. Additionally, rising R&D spending, the entry of new vaccine producers in nations like China and India, and a rise in regional tourism, and medical tourism are all driving market expansion in the area.

Europe is the second-largest market for encephalitis vaccines, due to the high frequency of encephalitis and the availability of new vaccinations.

Major vendors in Global Encephalitis Vaccines Market include Liaoning Cheng Bio Co, Wuhan Institute of Biological Products, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline plc, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, and other key players.

key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In September 2022, to safeguard those most in danger, NSW increased free access to the Japanese encephalitis (JE) vaccination for those living in impacted regional regions.

• In September 2021, The Japanese encephalitis (JE) vaccine maker Valneva SE announced that the US Department of Defense (DoD) has exercised the first option under a contract signed in September 2020 to buy more of its IXIARO vaccine.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Encephalitis Vaccines Market based on the below mentioned segments:

Global Encephalitis Vaccines Market, By Vaccine Type

• Mouse Brain-Derived Inactivated Vaccine
• Cell Culture-Derived Inactivated Vaccine
• Cell Culture-Derived Live Attenuated Vaccine

Global Encephalitis Vaccines Market, By Indication Type

• Japanese Encephalitis
• Tick-Borne Encephalitis
• Rabies Encephalitis

Global Encephalitis Vaccines Market, By End Users

• Child
• Adult

Encephalitis Vaccines Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter